Optimal infused CD34⁺ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation.

ABSTRACT: Autologous transplantation remains the standard of care for eligible multiple myeloma (MM) patients, yet optimal CD34⁺ cell dose remains unclear. We conducted a retrospective study on MM patients undergoing upfront transplant between 2005 and 2021 and divided them into low (≤2.5 × 10⁶ cells/kg) and high (>2.5 × 10⁶ cells/kg) CD34⁺ dose groups. We included 2479 patients, 95 in the low CD34⁺ group and 2384 in the high CD34⁺ group. Patients in the low CD34⁺ group were older (63.2 vs 61.1 years, p = 0.013), more often had R-ISS III (19% vs 9%, p = 0.014), received plerixafor (60% vs 35%, p < 0.001) and transplanted after 2009 (88% vs 80%, p = 0.047). Time to neutrophil and platelet recovery was longer in the low CD34<

SUBMITTER: Pasvolsky O 

PROVIDER: S-EPMC11527997 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature